Yugang Liu1, Hongyan Wu2, Yanpeng Zhu3, Yunshu Gao4. 1. Department of Orthopaedics, 401 Hospital of PLA Qingdao 266071, Shandong Province, China. 2. Department of Obstetrics And Gynecology, General Hospital of Bei Jing Command of PLA Beijing, China. 3. Department of General Surgery, 401 Hospital of PLA Qingdao 266071, Shandong Province, China. 4. Department of Oncology, 401 Hospital of PLA Qingdao 266071, Shandong Province, China.
Abstract
OBJECTIVE: Abundance of evidence implicated that leptin may play a decisive role in cancer occurrence, but the reported results varied across the individually published studies. The objective of this study is to access to what extent the extensively studied -2548G/A polymorphism of LEP gene acts on the onset of multiple cancers. METHODS: Eligible studies included in this meta-analysis were identified electronically in PubMed and Embase, and manually in relevant literature. Crude odds ratio (OR) with corresponding 95% confidence interval (CI) was calculated to estimate the risk of cancer associated with the -2548G/A polymorphism. RESULTS: 12 association studies with a total of 5,618 cancer cases and 6,509 healthy controls were pooled into this meta-analysis. The results revealed that compared with the G allele, the A allele was associated with modestly increased risk of overall cancer (OR, 1.21; 95% CI, 1.02-1.44). Following further stratified analyses, a borderline association was indicated in prostate cancer (OR, 1.18; 95% CI, 1.00-1.39), breast cancer (OR, 1.11; 95% CI, 1.00-1.22) and Caucasians (OR, 1.19; 95% CI, 1.00-1.41). CONCLUSIONS: This meta-analysis reveals that the A allele of -2548G/A polymorphism may be a determinant of cancer development.
OBJECTIVE: Abundance of evidence implicated that leptin may play a decisive role in cancer occurrence, but the reported results varied across the individually published studies. The objective of this study is to access to what extent the extensively studied -2548G/A polymorphism of LEP gene acts on the onset of multiple cancers. METHODS: Eligible studies included in this meta-analysis were identified electronically in PubMed and Embase, and manually in relevant literature. Crude odds ratio (OR) with corresponding 95% confidence interval (CI) was calculated to estimate the risk of cancer associated with the -2548G/A polymorphism. RESULTS: 12 association studies with a total of 5,618 cancer cases and 6,509 healthy controls were pooled into this meta-analysis. The results revealed that compared with the G allele, the A allele was associated with modestly increased risk of overall cancer (OR, 1.21; 95% CI, 1.02-1.44). Following further stratified analyses, a borderline association was indicated in prostate cancer (OR, 1.18; 95% CI, 1.00-1.39), breast cancer (OR, 1.11; 95% CI, 1.00-1.22) and Caucasians (OR, 1.19; 95% CI, 1.00-1.41). CONCLUSIONS: This meta-analysis reveals that the A allele of -2548G/A polymorphism may be a determinant of cancer development.
Authors: Rebecca J Cleveland; Marilie D Gammon; Chang-Min Long; Mia M Gaudet; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella Journal: Breast Cancer Res Treat Date: 2009-08-21 Impact factor: 4.872